Main Industry
Biotechnology
Main Product/Service
1. Trastuzumab Biosimilar
2. CDMO Services
3. CRM197 Carrier Protein
4. COVID-19 Antigen Rapid Test
2. CDMO Services
3. CRM197 Carrier Protein
4. COVID-19 Antigen Rapid Test
The content above was translated by Ai
Founded Year
2012
Unified Business No.
54150737
Status
Active
Number of Employees
40
Total Paid-in
Capital
3,020,681,690 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
OTC listing(2019)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their biologics; the other is the product development operation unit where they hope to fully apply theirteam's experience and knowledge on biologics from biosimilars, biobetters to new drugs. EirGenix's goal is that every patient can afford high-quality biopharmaceutical drugs.
The content above was translated by Ai
